HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Gabriel N Hortobagyi Selected Research

Adjuvant Chemotherapy

6/2014Locoregional recurrence risk for patients with T1,2 breast cancer with 1-3 positive lymph nodes treated with mastectomy and systemic treatment.
3/2014Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer.
3/2012Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer.
11/2010Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers.
11/2010Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer.
8/2010Estrogen/progesterone receptor negativity and HER2 positivity predict locoregional recurrence in patients with T1a,bN0 breast cancer.
7/2010Adjuvant chemotherapy in early-stage breast cancer: what, when, and for whom?
3/2010Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer : long-term results from the University of Texas M. D. Anderson Cancer Center Study ID97-099.
5/2009Impact of diabetes mellitus on complications and outcomes of adjuvant chemotherapy in older patients with breast cancer.
10/2008Effect of molecular disease subsets on disease-free survival in randomized adjuvant chemotherapy trials for estrogen receptor-positive breast cancer.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Research Interface PRO additionally includes drill-down to evidence, articles by author, export to Excel, FDA Link and mobile subscription:
1 year subscription, $490.00 USD

Gabriel N Hortobagyi Research Topics

Disease

293Breast Neoplasms (Breast Cancer)
11/2014 - 01/2002
185Neoplasms (Cancer)
10/2014 - 01/2002
45Neoplasm Metastasis (Metastasis)
04/2014 - 06/2002
26Carcinoma (Carcinomatosis)
06/2007 - 05/2002
13Disease Progression
05/2013 - 04/2002
10Inflammatory Breast Neoplasms
01/2014 - 02/2004
8Residual Neoplasm
02/2012 - 04/2004
7Circulating Neoplastic Cells
11/2014 - 04/2009
7Neutropenia
05/2012 - 01/2003
5Noninfiltrating Intraductal Carcinoma (DCIS)
10/2014 - 06/2002
5Heart Failure
11/2013 - 11/2002
4Ovarian Neoplasms (Ovarian Cancer)
10/2014 - 11/2002
4Infection
05/2012 - 10/2002
4Pancreatic Neoplasms (Pancreatic Cancer)
01/2011 - 10/2002
3Obesity
07/2014 - 09/2008
3Hypertension (High Blood Pressure)
11/2013 - 09/2007
3Male Breast Neoplasms (Male Breast Cancer)
05/2013 - 06/2002
3Hypersensitivity (Allergy)
01/2013 - 05/2002
3Pneumonia (Pneumonitis)
02/2012 - 07/2002
2Inflammation
07/2014 - 08/2007
2Coronary Artery Disease (Coronary Atherosclerosis)
11/2013 - 09/2007
2Peripheral Nervous System Diseases (PNS Diseases)
07/2013 - 11/2012
2Overweight
01/2013 - 01/2011
2Fatigue
02/2012 - 02/2004
2Anemia
02/2012 - 05/2009

Drug/Important Bio-Agent (IBA)

56Estrogens (Estrogen)FDA Link
10/2014 - 01/2002
55HormonesIBA
02/2014 - 10/2002
41Doxorubicin (Adriamycin)FDA LinkGeneric
12/2011 - 01/2002
39trastuzumab (Herceptin)FDA Link
07/2014 - 04/2002
38Epidermal Growth Factor Receptor (EGF Receptor)IBA
10/2014 - 10/2002
37Cyclophosphamide (Cytoxan)FDA LinkGeneric
03/2012 - 01/2002
34Paclitaxel (Taxol)FDA LinkGeneric
06/2013 - 05/2002
32Fluorouracil (Carac)FDA LinkGeneric
03/2012 - 01/2002
28taxaneIBA
01/2014 - 02/2002
20Progesterone Receptors (Progesterone Receptor)IBA
05/2013 - 10/2002
19docetaxel (Taxotere)FDA Link
04/2014 - 01/2002
18Biological Markers (Surrogate Marker)IBA
02/2014 - 06/2002
15Phosphotransferases (Kinase)IBA
05/2014 - 05/2003
15TamoxifenFDA LinkGeneric
02/2012 - 01/2002
14DNA (Deoxyribonucleic Acid)IBA
12/2013 - 12/2006
14TaxoidsIBA
01/2013 - 05/2002
13everolimusFDA Link
09/2014 - 10/2007
12exemestane (Aromasin)FDA Link
09/2014 - 03/2004
12AnthracyclinesIBA
06/2012 - 09/2003
11Aromatase (CYP19)IBA
02/2014 - 03/2004
10Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
07/2014 - 06/2003
10Messenger RNA (mRNA)IBA
01/2013 - 06/2005
9capecitabine (Xeloda)FDA Link
03/2012 - 09/2003
8lapatinib (GW572016)FDA Link
07/2014 - 07/2008
8Proteins (Proteins, Gene)IBA
01/2013 - 09/2003
7Epidermal Growth Factor (EGF)IBA
10/2014 - 10/2007
6Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
10/2012 - 08/2007
6DiphosphonatesIBA
04/2012 - 10/2003
6Epirubicin (Ellence)FDA LinkGeneric
03/2012 - 06/2005
6Transcription Factors (Transcription Factor)IBA
02/2012 - 09/2003
6bevacizumabFDA Link
08/2011 - 10/2004
5Biological Tumor Markers (Tumor Markers)IBA
10/2014 - 10/2002
5ParaffinIBA
01/2013 - 04/2004
5anastrozole (Arimidex)FDA LinkGeneric
08/2012 - 06/2002
5Granulocyte Colony-Stimulating Factor (G-CSF)IBA
03/2011 - 01/2002
5erlotinib (CP 358,774)FDA Link
01/2011 - 06/2007
5Estrogen ReceptorsIBA
12/2006 - 05/2002
4Metformin (Glucophage)FDA LinkGeneric
07/2014 - 07/2009
4RNA (Ribonucleic Acid)IBA
02/2014 - 06/2003
4vinorelbine (Navelbine)FDA LinkGeneric
01/2014 - 01/2002
4Aromatase InhibitorsIBA
05/2013 - 02/2012
4ixabepilone (BMS 247550)FDA Link
11/2012 - 08/2007
4Cyclin D1IBA
05/2010 - 10/2002
3Filgrastim (Neupogen)FDA Link
01/2014 - 07/2003
3CyclinsIBA
01/2013 - 10/2006
3Protein Kinases (Protein Kinase)IBA
09/2012 - 02/2004
3zoledronic acid (zoledronate)FDA Link
04/2012 - 01/2005
3Selective Estrogen Receptor Modulators (SERM)IBA
02/2012 - 03/2004
3gemcitabineFDA Link
01/2011 - 05/2002
3CytotoxinsIBA
01/2011 - 05/2002
3Phenobarbital (Luminal)FDA Link
01/2011 - 08/2005
3Leucovorin (Folinic Acid)FDA Link
05/2010 - 06/2004
3thymidine 5'-triphosphate (TTP)IBA
05/2010 - 09/2004
3Cadherins (E-Cadherin)IBA
05/2010 - 12/2006
3Methotrexate (Mexate)FDA LinkGeneric
03/2010 - 11/2003
3tau Proteins (tau Protein)IBA
09/2009 - 06/2005
3Cyclin EIBA
01/2007 - 11/2002
2dasatinib (BMS 354825)FDA Link
10/2014 - 05/2010
2RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA
01/2014 - 05/2005
2Sirolimus (Rapamycin)FDA Link
08/2013 - 02/2012
2Formaldehyde (Formol)FDA Link
01/2013 - 05/2005
2triciribineIBA
09/2012 - 10/2007
2pamidronate (APD)FDA LinkGeneric
04/2012 - 06/2008

Therapy/Procedure

159Drug Therapy (Chemotherapy)
11/2014 - 01/2002
27Adjuvant Chemotherapy
06/2014 - 01/2002
20Radiotherapy
09/2011 - 06/2002
19Mastectomy (Mammectomy)
10/2014 - 01/2002
16Neoadjuvant Therapy
01/2013 - 10/2002
9Heterologous Transplantation (Xenotransplantation)
07/2014 - 10/2002
6Aftercare (After-Treatment)
12/2013 - 07/2002
4Segmental Mastectomy (Lumpectomy)
10/2009 - 07/2002
3Hematopoietic Stem Cell Transplantation
01/2012 - 11/2004
3Combination Drug Therapy (Combination Chemotherapy)
05/2011 - 02/2006
2Chemoprevention
02/2012 - 06/2002
2Therapeutics
01/2012 - 10/2004